Systemic delivery of biotherapeutic RNA to the myocardium transiently modulates cardiac contractility in vivo.
Publication/Presentation Date
7-22-2025
Abstract
Lipid nanoparticles (LNP) represent a versatile platform for improving delivery of therapeutic nucleic acids. Yet, delivery to the myocardium remains a formidable challenge due to local barriers in the heart and systemic hindrances. In particular, plasma apolipoprotein E (apoE) directs LNP to the liver, limiting potential extrahepatic delivery. Here, we report a cardiotropic LNP (cLNP), which within 30 min post-intravenous injection accumulates in the heart of ApoE knockout (
Volume
122
Issue
29
First Page
2409266122
Last Page
2409266122
ISSN
1091-6490
Published In/Presented At
Shuvaev, V. V., Tam, Y. K., Lee, B. W., Myerson, J. W., Herbst, A., Kiseleva, R. Y., Glassman, P. M., Parhiz, H., Alameh, M. G., Pardi, N., Muramatsu, H., Shuvaeva, T. I., Arguiri, E., Marcos-Contreras, O. A., Hood, E. D., Brysgel, T. V., Nong, J., Papp, T. E., Eaton, D. M., Riley, R., … Muzykantov, V. R. (2025). Systemic delivery of biotherapeutic RNA to the myocardium transiently modulates cardiac contractility in vivo. Proceedings of the National Academy of Sciences of the United States of America, 122(29), e2409266122. https://doi.org/10.1073/pnas.2409266122
Disciplines
Medicine and Health Sciences
PubMedID
40668829
Department(s)
Department of Surgery
Document Type
Article